[go: up one dir, main page]

CL2018002009A1 - Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. - Google Patents

Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.

Info

Publication number
CL2018002009A1
CL2018002009A1 CL2018002009A CL2018002009A CL2018002009A1 CL 2018002009 A1 CL2018002009 A1 CL 2018002009A1 CL 2018002009 A CL2018002009 A CL 2018002009A CL 2018002009 A CL2018002009 A CL 2018002009A CL 2018002009 A1 CL2018002009 A1 CL 2018002009A1
Authority
CL
Chile
Prior art keywords
compounds
cholestatic
fibrotic
treatment
pharmaceutical composition
Prior art date
Application number
CL2018002009A
Other languages
English (en)
Inventor
Haiying He
Hualing Xiao
Peng Li
Chunyan Du
Zhi Luo
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CL2018002009A1 publication Critical patent/CL2018002009A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.
CL2018002009A 2016-01-28 2018-07-24 Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. CL2018002009A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610061293 2016-01-28
CN201610331759 2016-05-18

Publications (1)

Publication Number Publication Date
CL2018002009A1 true CL2018002009A1 (es) 2018-11-05

Family

ID=59397430

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002009A CL2018002009A1 (es) 2016-01-28 2018-07-24 Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.

Country Status (15)

Country Link
US (2) US10875888B2 (es)
EP (1) EP3409684B1 (es)
JP (1) JP6924765B2 (es)
KR (1) KR102788843B1 (es)
CN (1) CN109071593B (es)
AU (2) AU2017213032B2 (es)
CA (1) CA3012396C (es)
CL (1) CL2018002009A1 (es)
IL (1) IL260795B (es)
MX (1) MX391812B (es)
MY (1) MY196292A (es)
PH (1) PH12018550120B1 (es)
SG (2) SG11201806348PA (es)
WO (1) WO2017129125A1 (es)
ZA (1) ZA201805231B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
AU2016242861B2 (en) 2015-03-31 2020-08-20 Enanta Phamraceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PH12018550120B1 (en) * 2016-01-28 2023-03-15 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid derivative fxr agonist
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112019010798A2 (pt) 2016-11-29 2019-10-01 Enanta Pharm Inc processo para preparação de derivados de ácidos biliares de sulfonilureia
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN109134572A (zh) * 2017-06-19 2019-01-04 中国科学院上海药物研究所 胆酸衍生物及其制备方法和用途
WO2019020068A1 (zh) * 2017-07-26 2019-01-31 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途
WO2019020067A1 (zh) * 2017-07-26 2019-01-31 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂的制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
WO2019085963A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团股份有限公司 一种胆酸类化合物的制备方法
CN107722000A (zh) * 2017-11-03 2018-02-23 中国药科大学 9位－取代的小檗碱衍生物的制备及其医药用途
CN107987116B (zh) * 2018-01-17 2021-01-05 中国药科大学 一类鹅去氧胆酸衍生物、其制备方法和医药用途
CN116178473B (zh) * 2018-12-10 2025-03-04 江西科睿药业有限公司 一种奥贝胆酸的制备方法
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
CN110878113B (zh) * 2019-11-07 2021-02-02 成都贝诺科成生物科技有限公司 一种具有抗菌活性的胆酸衍生物及其药用组合物
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN111518152B (zh) * 2020-04-23 2022-11-22 江西青峰药业有限公司 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的制备方法及其应用
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN113861258A (zh) * 2021-09-05 2021-12-31 中国海洋大学 一种马尾藻甾醇的合成方法
KR20230043774A (ko) * 2021-09-24 2023-03-31 (주)샤페론 염증복합체 억제제를 유효성분으로 하는 아토피 피부염 예방, 개선 또는 치료용 약학 조성물
WO2023048526A1 (ko) * 2021-09-24 2023-03-30 (주)샤페론 염증복합체 억제제를 유효성분으로 함유하는, 비알코올성 지방간염, 간 섬유화의 예방, 개선 또는 치료용 약학적 조성물
IT202200011705A1 (it) * 2022-06-01 2023-12-01 Prec Bio Therapeutics S R L Derivati del colesterolo e loro usi
CN116497082B (zh) * 2023-06-27 2023-09-29 华南理工大学 一种化学-酶法合成3α,7α,24R-三羟基胆甾醇的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
DK1392714T3 (da) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
MX2014013150A (es) * 2012-05-01 2015-05-11 Catabasis Pharmaceuticals Inc Conjugados de acidos grasos de estatina y agonistas fxr, composiciones y metodos de uso.
CN105377870B (zh) * 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
KR102354931B1 (ko) * 2014-08-20 2022-01-24 에프. 호프만-라 로슈 아게 모사된 생리학적 환경에서 물질의 거동을 분석하기 위한 시험관내 방법 및 장치
US10208081B2 (en) * 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
AU2016242861B2 (en) * 2015-03-31 2020-08-20 Enanta Phamraceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN106083978A (zh) * 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
EP3290429A1 (en) * 2015-04-28 2018-03-07 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof
PH12018550120B1 (en) * 2016-01-28 2023-03-15 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid derivative fxr agonist
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
EP3436316A4 (en) * 2016-03-31 2020-03-04 B/E Aerospace, Inc. SYSTEM AND METHODS FOR PROTECTING A PASSENGER IN AN OBLIQUE MOUNTED AIRPLANE SEAT

Also Published As

Publication number Publication date
JP2019503392A (ja) 2019-02-07
EP3409684A1 (en) 2018-12-05
US11667667B2 (en) 2023-06-06
MX2018009175A (es) 2018-11-29
CN109071593B (zh) 2021-01-15
EP3409684B1 (en) 2024-01-03
AU2021202018A1 (en) 2021-04-29
US20190382437A1 (en) 2019-12-19
CN109071593A (zh) 2018-12-21
AU2017213032B2 (en) 2021-01-07
KR20180100703A (ko) 2018-09-11
JP6924765B2 (ja) 2021-08-25
BR112018015474A2 (pt) 2018-12-18
PH12018550120B1 (en) 2023-03-15
WO2017129125A1 (zh) 2017-08-03
US10875888B2 (en) 2020-12-29
AU2021202018B2 (en) 2022-04-07
EP3409684A4 (en) 2019-10-09
SG11201806348PA (en) 2018-08-30
AU2017213032A1 (en) 2018-08-30
MX391812B (es) 2025-03-21
MY196292A (en) 2023-03-24
PH12018550120A1 (en) 2019-03-18
US20210040140A1 (en) 2021-02-11
KR102788843B1 (ko) 2025-03-28
CA3012396A1 (en) 2017-08-03
SG10201913768TA (en) 2020-03-30
ZA201805231B (en) 2022-03-30
CA3012396C (en) 2024-03-26
NZ745250A (en) 2024-08-30
IL260795B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX388378B (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201692298A1 (ru) Производные карбоксамидов
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
BR112018014622A2 (pt) ?composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar uma infecção por hiv e para prevenir uma infecção por hiv, e, uso de um composto ou sal?